In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Biogen Inc (NASDAQ: BIIB) closed at $153.43 up 2.75% from its previous closing price of $149.33. In other words, the price has increased by $2.75 from its previous closing price. On the day, 1.81 million shares were traded. BIIB stock price reached its highest trading level at $153.66 during the session, while it also had its lowest trading level at $148.9.
Ratios:
For a deeper understanding of Biogen Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.68 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.77. For the most recent quarter (mrq), Quick Ratio is recorded 2.04 and its Current Ratio is at 2.72. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on September 25, 2025, initiated with a Buy rating and assigned the stock a target price of $190.
HSBC Securities Downgraded its Buy to Hold on April 28, 2025, while the target price for the stock was maintained at $118.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 02 ’25 when Singhal Priya sold 517 shares for $133.55 per share. The transaction valued at 69,045 led to the insider holds 5,772 shares of the business.
Singhal Priya bought 517 shares of BIIB for $69,045 on Sep 02 ’25. On Jul 08 ’25, another insider, Izzar Rachid, who serves as the Head of Global Product Strat. of the company, sold 2,223 shares for $135.00 each. As a result, the insider received 300,105 and left with 6,330 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 22508527616 and an Enterprise Value of 25138229248. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.99, and their Forward P/E ratio for the next fiscal year is 10.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.32 while its Price-to-Book (P/B) ratio in mrq is 1.24. Its current Enterprise Value per Revenue stands at 2.497 whereas that against EBITDA is 7.373.
Stock Price History:
The Beta on a monthly basis for BIIB is 0.15, which has changed by -0.14138687 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, BIIB has reached a high of $179.20, while it has fallen to a 52-week low of $110.04. The 50-Day Moving Average of the stock is 5.67%, while the 200-Day Moving Average is calculated to be 13.33%.
Shares Statistics:
For the past three months, BIIB has traded an average of 1.63M shares per day and 1852180 over the past ten days. A total of 146.70M shares are outstanding, with a floating share count of 146.43M. Insiders hold about 0.19% of the company’s shares, while institutions hold 92.95% stake in the company. Shares short for BIIB as of 1760486400 were 5191008 with a Short Ratio of 3.19, compared to 1757894400 on 5125778. Therefore, it implies a Short% of Shares Outstanding of 5191008 and a Short% of Float of 4.5700002.
Earnings Estimates
The performance of Biogen Inc (BIIB) in the stock market is under the watchful eye of 25.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $3.62, with high estimates of $5.06 and low estimates of $2.83.
Analysts are recommending an EPS of between $16.43 and $14.61 for the fiscal current year, implying an average EPS of $15.12. EPS for the following year is $15.32, with 32.0 analysts recommending between $17.81 and $11.01.
Revenue Estimates
A total of 25 analysts believe the company’s revenue will be $2.22B this quarter.It ranges from a high estimate of $2.5B to a low estimate of $2.1B. As of. The current estimate, Biogen Inc’s year-ago sales were $2.45BFor the next quarter, 25 analysts are estimating revenue of $2.27B. There is a high estimate of $2.33B for the next quarter, whereas the lowest estimate is $2.17B.
A total of 28 analysts have provided revenue estimates for BIIB’s current fiscal year. The highest revenue estimate was $10.13B, while the lowest revenue estimate was $9.7B, resulting in an average revenue estimate of $9.82B. In the same quarter a year ago, actual revenue was $9.68BBased on 33 analysts’ estimates, the company’s revenue will be $9.29B in the next fiscal year. The high estimate is $9.82B and the low estimate is $8.61B.
